Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

Yuan Hung Kuo, Sheng Nan Lu, Yen Yang Chen, Kwong Ming Kee, Yi Hao Yen, Chao Hung Hung, Tsung Hui Hu, Chien Hung Chen, Jing Houng Wang*

*此作品的通信作者

研究成果: 期刊稿件評論/辯論

10 引文 斯高帕斯(Scopus)

摘要

In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”. A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

原文英語
文章編號823960
期刊Frontiers in Oncology
11
DOIs
出版狀態已出版 - 14 12 2021

文獻附註

Publisher Copyright:
© 2021 Kuo, Lu, Chen, Kee, Yen, Hung, Hu, Chen and Wang.

指紋

深入研究「Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)」主題。共同形成了獨特的指紋。

引用此